State-of-the-art glucocorticoid-targeted drug therapies for the treatment of rheumatoid arthritis

被引:6
|
作者
Pelechas, Eleftherios [1 ]
Drosos, Alexandros A. [1 ]
机构
[1] Univ Ioannina, Med Sch, Dept Internal Med, Rheumatol Clin, Ioannina 45110, Greece
关键词
DMARDs; glucocorticoids; liposomal treatment; rheumatoid arthritis; treatment strategies; COBRA COMBINATION THERAPY; DOUBLE-BLIND; LONG; RECOMMENDATIONS; MANAGEMENT; RECEPTOR; TRIAL; PREDNISONE; MECHANISMS; EFFICACY;
D O I
10.1080/14656566.2022.2049238
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction Glucocorticoids are steroid hormones broadly used for the treatment of several inflammatory and autoimmune diseases among other numerous indications, including rheumatoid arthritis. Areas covered For the purposes of this article, the authors have performed an extensive review of the literature to present the latest studies on glucocorticoid use in rheumatoid arthritis. They also provide the reader with their expert perspectives on future developments. Expert opinion The authors do not anticipate that glucocorticoids with be replaced in the near future by newer drugs. As such, rheumatologists should be fully aware of the possible side-effects and educate appropriately their patients to recognize and report them. Newer formulations, such as the liposomal/nanoparticle-based treatments, will result in less pronounced adverse effects, but the input of clinical experience along with the current recommendations for the glucocorticoid use will benefit both clinicians and patients with rheumatoid arthritis.
引用
收藏
页码:703 / 711
页数:9
相关论文
共 50 条
  • [31] The recent progress of γδ T cells and its targeted therapies in rheumatoid arthritis
    Feng, Xue
    Xu, Yan
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2024, 27 (11)
  • [32] Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples
    Combe, Bernard
    van Vollenhoven, Ronald
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (09) : 1433 - 1435
  • [33] Recent approaches for targeted drug delivery in rheumatoid arthritis diagnosis and treatment
    Chegini, Sana Pirmardvand
    Varshosaz, Jaleh
    Taymouri, Somayeh
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2018, 46 : 502 - 514
  • [34] Intra-articular glucocorticoid injections should not be neglected in the remission targeted treatment of early rheumatoid arthritis: a post hoc analysis from the NEO-RACo trial
    Kuusalo, L. A.
    Puolakka, K. T.
    Kautiainen, H.
    Alasaarela, E. M.
    Hannonen, P. J.
    Julkunen, H. A.
    Kaipiainen-Seppanen, O. A.
    Korpela, M. M.
    Mottonen, T. T.
    Paimela, L. H.
    Peltomaa, R. L.
    Yli-Kerttula, T. K.
    Leirisalo-Repo, M.
    Rantalaiho, V. M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (06) : 1038 - 1044
  • [35] New and future drug therapies for rheumatoid arthritis
    Simon, LS
    Yocum, D
    RHEUMATOLOGY, 2000, 39 : 36 - 42
  • [36] Development of TNF inhibitor therapies for the treatment of rheumatoid arthritis
    Furst, D. E.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (03) : S5 - S12
  • [37] State-of-the-art therapies for fragile X syndrome
    Protic, Dragana
    Hagerman, Randi
    DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2024, 66 (07) : 863 - 871
  • [38] Immunotherapy: State-of-the-art review of therapies and theratypes
    Agache, Ioana
    Zemelka-Wiacek, Magdalena
    Shamji, Mohamed H.
    Jutel, Marek
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 150 (06) : 1279 - 1288
  • [39] Endoluminal bariatric and metabolic therapies: state-of-the-art
    Bakheet, Nader
    Badurdeen, Dilhana
    Sartoretto, Adrian
    Kumbhari, Vivek
    CURRENT OPINION IN GASTROENTEROLOGY, 2023, 39 (05) : 362 - 369
  • [40] RHEUMATOID-ARTHRITIS - STATUS OF DRUG THERAPIES
    MONCUR, C
    WILLIAMS, HJ
    PHYSICAL THERAPY, 1995, 75 (06): : 511 - 525